PL182680B1 - Nowe inhibitory skupiania się płytek krwi - Google Patents

Nowe inhibitory skupiania się płytek krwi

Info

Publication number: PL182680B1
Authority: PL; Poland
Prior art keywords: group; formula; acid; triazolo; pyrimidin
Prior art date: 1995-07-11

Application number

PL96324396A

Other languages

English (en)

Polish (pl)

Other versions

PL324396A1 (en

Inventor

David Cox

Anthony Ingall

Paul Willis

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-11

Filing date

1996-07-04

Publication date

2002-02-28

1995-07-11 Priority claimed from GBGB9514074.5A external-priority patent/GB9514074D0/en

1995-10-05 Priority claimed from GBGB9520311.3A external-priority patent/GB9520311D0/en

1995-11-08 Priority claimed from GBGB9522837.5A external-priority patent/GB9522837D0/en

1996-07-04 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

1998-05-25 Publication of PL324396A1 publication Critical patent/PL324396A1/xx

2002-02-28 Publication of PL182680B1 publication Critical patent/PL182680B1/pl

Links

239000003112 inhibitor Substances 0.000 title claims description 3
230000002776 aggregation Effects 0.000 title claims 4
238000005054 agglomeration Methods 0.000 title 1
210000001772 blood platelet Anatomy 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 201
125000000217 alkyl group Chemical group 0.000 claims abstract description 54
150000003839 salts Chemical class 0.000 claims abstract description 45
125000006701 (C1-C7) alkyl group Chemical group 0.000 claims abstract description 10
229910052736 halogen Inorganic materials 0.000 claims abstract description 9
150000002367 halogens Chemical class 0.000 claims abstract description 9
229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 9
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
229910052717 sulfur Inorganic materials 0.000 claims abstract description 8
239000000651 prodrug Substances 0.000 claims abstract description 5
229940002612 prodrug Drugs 0.000 claims abstract description 5
-1 5-tetrazolyl Chemical group 0.000 claims abstract 187
239000000543 intermediate Substances 0.000 claims abstract 5
239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
230000002265 prevention Effects 0.000 claims abstract 4
229910052739 hydrogen Inorganic materials 0.000 claims description 32
239000002253 acid Substances 0.000 claims 133
239000000047 product Substances 0.000 claims 133
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 102
238000000034 method Methods 0.000 claims 96
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 90
239000000243 solution Substances 0.000 claims 72
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 64
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 claims 54
125000006309 butyl amino group Chemical group 0.000 claims 52
239000002904 solvent Substances 0.000 claims 51
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 49
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 46
125000006239 protecting group Chemical group 0.000 claims 45
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 38
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 38
238000006243 chemical reaction Methods 0.000 claims 37
229910004298 SiO 2 Inorganic materials 0.000 claims 32
239000003480 eluent Substances 0.000 claims 32
239000011541 reaction mixture Substances 0.000 claims 30
239000001257 hydrogen Substances 0.000 claims 29
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 28
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 27
238000004587 chromatography analysis Methods 0.000 claims 27
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 26
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 25
239000000203 mixture Substances 0.000 claims 24
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 23
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 22
239000012442 inert solvent Substances 0.000 claims 20
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 19
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 19
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 18
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 18
150000002148 esters Chemical class 0.000 claims 18
125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 18
238000011282 treatment Methods 0.000 claims 18
239000002585 base Substances 0.000 claims 17
229960000583 acetic acid Drugs 0.000 claims 16
238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims 16
125000004494 ethyl ester group Chemical group 0.000 claims 14
159000000000 sodium salts Chemical class 0.000 claims 13
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 12
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 claims 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 12
239000007787 solid Substances 0.000 claims 12
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims 11
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 11
229920006395 saturated elastomer Polymers 0.000 claims 11
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 10
239000003795 chemical substances by application Substances 0.000 claims 10
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 10
238000010992 reflux Methods 0.000 claims 10
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 9
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 9
239000003146 anticoagulant agent Substances 0.000 claims 9
125000003118 aryl group Chemical group 0.000 claims 9
239000003054 catalyst Substances 0.000 claims 9
230000007062 hydrolysis Effects 0.000 claims 9
238000006460 hydrolysis reaction Methods 0.000 claims 9
230000008569 process Effects 0.000 claims 9
230000009467 reduction Effects 0.000 claims 9
229910000030 sodium bicarbonate Inorganic materials 0.000 claims 9
235000017557 sodium bicarbonate Nutrition 0.000 claims 9
229910000104 sodium hydride Inorganic materials 0.000 claims 9
125000000446 sulfanediyl group Chemical group *S* 0.000 claims 9
239000000725 suspension Substances 0.000 claims 9
AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 8
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 8
230000002378 acidificating effect Effects 0.000 claims 8
239000012312 sodium hydride Substances 0.000 claims 8
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 8
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 7
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 7
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 7
239000012298 atmosphere Substances 0.000 claims 7
229910052500 inorganic mineral Inorganic materials 0.000 claims 7
235000010755 mineral Nutrition 0.000 claims 7
239000011707 mineral Substances 0.000 claims 7
150000007524 organic acids Chemical class 0.000 claims 7
229910052763 palladium Inorganic materials 0.000 claims 7
238000003756 stirring Methods 0.000 claims 7
229910052723 transition metal Inorganic materials 0.000 claims 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
230000000694 effects Effects 0.000 claims 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
238000001914 filtration Methods 0.000 claims 6
238000005984 hydrogenation reaction Methods 0.000 claims 6
230000003647 oxidation Effects 0.000 claims 6
238000007254 oxidation reaction Methods 0.000 claims 6
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 6
150000003624 transition metals Chemical class 0.000 claims 6
XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 claims 6
JEKXDBJKESFWRL-UHFFFAOYSA-N (2,2-dimethyl-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]dioxol-4-yl)methanol Chemical compound C1CC(CO)C2OC(C)(C)OC21 JEKXDBJKESFWRL-UHFFFAOYSA-N 0.000 claims 5
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 5
125000002252 acyl group Chemical group 0.000 claims 5
239000005557 antagonist Substances 0.000 claims 5
239000000706 filtrate Substances 0.000 claims 5
125000005843 halogen group Chemical group 0.000 claims 5
230000002140 halogenating effect Effects 0.000 claims 5
150000007522 mineralic acids Chemical class 0.000 claims 5
239000012038 nucleophile Substances 0.000 claims 5
238000011321 prophylaxis Methods 0.000 claims 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 5
239000011734 sodium Substances 0.000 claims 5
230000001732 thrombotic effect Effects 0.000 claims 5
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 4
STUQITWXBMZUGY-UHFFFAOYSA-N 6-hydroxy-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound OC1=CC(O)=NC(S)=N1 STUQITWXBMZUGY-UHFFFAOYSA-N 0.000 claims 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 4
QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
238000002835 absorbance Methods 0.000 claims 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 4
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims 4
239000012346 acetyl chloride Substances 0.000 claims 4
230000000702 anti-platelet effect Effects 0.000 claims 4
239000007864 aqueous solution Substances 0.000 claims 4
230000004087 circulation Effects 0.000 claims 4
238000001816 cooling Methods 0.000 claims 4
238000006193 diazotization reaction Methods 0.000 claims 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
150000004820 halides Chemical class 0.000 claims 4
NGAZZOYFWWSOGK-UHFFFAOYSA-N heptan-3-one Chemical compound CCCCC(=O)CC NGAZZOYFWWSOGK-UHFFFAOYSA-N 0.000 claims 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
238000006772 olefination reaction Methods 0.000 claims 4
239000012044 organic layer Substances 0.000 claims 4
239000012074 organic phase Substances 0.000 claims 4
229910052698 phosphorus Inorganic materials 0.000 claims 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
229910052708 sodium Inorganic materials 0.000 claims 4
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims 4
238000012360 testing method Methods 0.000 claims 4
229910052727 yttrium Inorganic materials 0.000 claims 4
UGRVYFQFDZRNMQ-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonohydrazide Chemical compound CC(C)C1=CC(C(C)C)=C(S(=O)(=O)NN)C(C(C)C)=C1 UGRVYFQFDZRNMQ-UHFFFAOYSA-N 0.000 claims 3
IQGYCVKWCYGVBK-UHFFFAOYSA-N 5,6-diamino-1h-pyrimidine-2,4-dithione Chemical compound NC=1NC(=S)NC(=S)C=1N IQGYCVKWCYGVBK-UHFFFAOYSA-N 0.000 claims 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
206010002388 Angina unstable Diseases 0.000 claims 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
208000007814 Unstable Angina Diseases 0.000 claims 3
229960001138 acetylsalicylic acid Drugs 0.000 claims 3
230000009471 action Effects 0.000 claims 3
238000004220 aggregation Methods 0.000 claims 3
239000000556 agonist Substances 0.000 claims 3
229910052783 alkali metal Inorganic materials 0.000 claims 3
150000001408 amides Chemical class 0.000 claims 3
229910021529 ammonia Inorganic materials 0.000 claims 3
150000003863 ammonium salts Chemical class 0.000 claims 3
229960004676 antithrombotic agent Drugs 0.000 claims 3
230000000740 bleeding effect Effects 0.000 claims 3
239000003153 chemical reaction reagent Substances 0.000 claims 3
229910052801 chlorine Inorganic materials 0.000 claims 3
238000007796 conventional method Methods 0.000 claims 3
208000035475 disorder Diseases 0.000 claims 3
239000003814 drug Substances 0.000 claims 3
238000001704 evaporation Methods 0.000 claims 3
230000008020 evaporation Effects 0.000 claims 3
238000004108 freeze drying Methods 0.000 claims 3
239000008103 glucose Substances 0.000 claims 3
238000010438 heat treatment Methods 0.000 claims 3
230000003301 hydrolyzing effect Effects 0.000 claims 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
238000001802 infusion Methods 0.000 claims 3
201000004332 intermediate coronary syndrome Diseases 0.000 claims 3
239000008101 lactose Substances 0.000 claims 3
229910052751 metal Inorganic materials 0.000 claims 3
239000002184 metal Substances 0.000 claims 3
YWOITFUKFOYODT-UHFFFAOYSA-N methanol;sodium Chemical compound [Na].OC YWOITFUKFOYODT-UHFFFAOYSA-N 0.000 claims 3
239000011259 mixed solution Substances 0.000 claims 3
208000010125 myocardial infarction Diseases 0.000 claims 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
239000003921 oil Substances 0.000 claims 3
235000006408 oxalic acid Nutrition 0.000 claims 3
239000007800 oxidant agent Substances 0.000 claims 3
230000001590 oxidative effect Effects 0.000 claims 3
210000004623 platelet-rich plasma Anatomy 0.000 claims 3
238000000746 purification Methods 0.000 claims 3
238000011946 reduction process Methods 0.000 claims 3
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims 3
229910000033 sodium borohydride Inorganic materials 0.000 claims 3
239000012279 sodium borohydride Substances 0.000 claims 3
239000011780 sodium chloride Substances 0.000 claims 3
239000007858 starting material Substances 0.000 claims 3
238000001356 surgical procedure Methods 0.000 claims 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 2
BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 2
BLXSFCHWMBESKV-UHFFFAOYSA-N 1-iodopentane Chemical compound CCCCCI BLXSFCHWMBESKV-UHFFFAOYSA-N 0.000 claims 2
HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 claims 2
OSKSVLBJJXQUPI-UHFFFAOYSA-N 2h-triazole-4-carboxamide Chemical compound NC(=O)C1=CNN=N1 OSKSVLBJJXQUPI-UHFFFAOYSA-N 0.000 claims 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims 2
IJIBRSFAXRFPPN-UHFFFAOYSA-N 5-bromo-2-methoxybenzaldehyde Chemical compound COC1=CC=C(Br)C=C1C=O IJIBRSFAXRFPPN-UHFFFAOYSA-N 0.000 claims 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims 2
239000005695 Ammonium acetate Substances 0.000 claims 2
201000001320 Atherosclerosis Diseases 0.000 claims 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 2
208000032843 Hemorrhage Diseases 0.000 claims 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
102100025306 Integrin alpha-IIb Human genes 0.000 claims 2
101710149643 Integrin alpha-IIb Proteins 0.000 claims 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
238000003527 Peterson olefination reaction Methods 0.000 claims 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims 2
108090000190 Thrombin Proteins 0.000 claims 2
208000007536 Thrombosis Diseases 0.000 claims 2
206010047115 Vasculitis Diseases 0.000 claims 2
206010047249 Venous thrombosis Diseases 0.000 claims 2
238000007239 Wittig reaction Methods 0.000 claims 2
239000003377 acid catalyst Substances 0.000 claims 2
238000005903 acid hydrolysis reaction Methods 0.000 claims 2
230000004913 activation Effects 0.000 claims 2
238000011360 adjunctive therapy Methods 0.000 claims 2
150000001298 alcohols Chemical class 0.000 claims 2
150000003973 alkyl amines Chemical class 0.000 claims 2
239000002168 alkylating agent Substances 0.000 claims 2
229940100198 alkylating agent Drugs 0.000 claims 2
238000005804 alkylation reaction Methods 0.000 claims 2
229940043376 ammonium acetate Drugs 0.000 claims 2
235000019257 ammonium acetate Nutrition 0.000 claims 2
235000011114 ammonium hydroxide Nutrition 0.000 claims 2
229940127219 anticoagulant drug Drugs 0.000 claims 2
150000001540 azides Chemical class 0.000 claims 2
229910052796 boron Inorganic materials 0.000 claims 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims 2
239000012267 brine Substances 0.000 claims 2
125000002837 carbocyclic group Chemical group 0.000 claims 2
150000001728 carbonyl compounds Chemical class 0.000 claims 2
239000000460 chlorine Substances 0.000 claims 2
238000007887 coronary angioplasty Methods 0.000 claims 2
239000007822 coupling agent Substances 0.000 claims 2
238000007257 deesterification reaction Methods 0.000 claims 2
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 claims 2
RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims 2
229910000071 diazene Inorganic materials 0.000 claims 2
238000004090 dissolution Methods 0.000 claims 2
GVLZIMQSYQDAHB-QRPNPIFTSA-N ditert-butyl (2s)-2-aminobutanedioate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)C[C@H](N)C(=O)OC(C)(C)C GVLZIMQSYQDAHB-QRPNPIFTSA-N 0.000 claims 2
238000001035 drying Methods 0.000 claims 2
125000003720 ethoxymethylidene group Chemical group [H]C(=*)OC([H])([H])C([H])([H])[H] 0.000 claims 2
239000000284 extract Substances 0.000 claims 2
239000012362 glacial acetic acid Substances 0.000 claims 2
229960002897 heparin Drugs 0.000 claims 2
229920000669 heparin Polymers 0.000 claims 2
238000004128 high performance liquid chromatography Methods 0.000 claims 2
230000005764 inhibitory process Effects 0.000 claims 2
208000014674 injury Diseases 0.000 claims 2
239000003456 ion exchange resin Substances 0.000 claims 2
229920003303 ion-exchange polymer Polymers 0.000 claims 2
OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 claims 2
150000003951 lactams Chemical class 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
229910000000 metal hydroxide Inorganic materials 0.000 claims 2
150000004692 metal hydroxides Chemical class 0.000 claims 2
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 2
PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 claims 2
238000006396 nitration reaction Methods 0.000 claims 2
150000002826 nitrites Chemical class 0.000 claims 2
150000002905 orthoesters Chemical class 0.000 claims 2
230000037361 pathway Effects 0.000 claims 2
239000011574 phosphorus Substances 0.000 claims 2
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
229920001467 poly(styrenesulfonates) Polymers 0.000 claims 2
239000002243 precursor Substances 0.000 claims 2
238000002360 preparation method Methods 0.000 claims 2
150000003230 pyrimidines Chemical class 0.000 claims 2
125000001453 quaternary ammonium group Chemical group 0.000 claims 2
229940044551 receptor antagonist Drugs 0.000 claims 2
239000002464 receptor antagonist Substances 0.000 claims 2
108020003175 receptors Proteins 0.000 claims 2
102000005962 receptors Human genes 0.000 claims 2
235000010288 sodium nitrite Nutrition 0.000 claims 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 2
125000001424 substituent group Chemical group 0.000 claims 2
239000006228 supernatant Substances 0.000 claims 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims 2
229960004072 thrombin Drugs 0.000 claims 2
150000003852 triazoles Chemical class 0.000 claims 2
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims 2
238000005406 washing Methods 0.000 claims 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
229930182837 (R)-adrenaline Natural products 0.000 claims 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims 1
AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 claims 1
125000004707 1-methylethylthio group Chemical group CC(C)S* 0.000 claims 1
SODVEDDQLXKHHZ-UHFFFAOYSA-N 2,6-bis(propylsulfanyl)pyrimidine-4,5-diamine Chemical compound CCCSC1=NC(N)=C(N)C(SCCC)=N1 SODVEDDQLXKHHZ-UHFFFAOYSA-N 0.000 claims 1
FDDPRBUXGVIDON-UHFFFAOYSA-N 2-(3,3,3-trifluoropropylsulfanyl)-1h-pyrimidine-4,6-dione Chemical compound FC(F)(F)CCSC1=NC(=O)CC(=O)N1 FDDPRBUXGVIDON-UHFFFAOYSA-N 0.000 claims 1
ZSDQQJHSRVEGTJ-UHFFFAOYSA-N 2-(6-amino-1h-indol-3-yl)acetonitrile Chemical compound NC1=CC=C2C(CC#N)=CNC2=C1 ZSDQQJHSRVEGTJ-UHFFFAOYSA-N 0.000 claims 1
APISVOVOJVZIBA-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC#N)C1=CC=CC=C1 APISVOVOJVZIBA-UHFFFAOYSA-N 0.000 claims 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
RCGLWQFNUOBKRT-UHFFFAOYSA-N 2-pentylsulfanyl-1h-pyrimidine-4,6-dione Chemical compound CCCCCSC1=NC(=O)CC(=O)N1 RCGLWQFNUOBKRT-UHFFFAOYSA-N 0.000 claims 1
125000004911 3,3-dimethylbutylamino group Chemical group CC(CCN*)(C)C 0.000 claims 1
OOXSPRVTTSGCQK-UHFFFAOYSA-N 4,6-dichloro-5-nitro-2-(3,3,3-trifluoropropylsulfanyl)pyrimidine Chemical compound [O-][N+](=O)C1=C(Cl)N=C(SCCC(F)(F)F)N=C1Cl OOXSPRVTTSGCQK-UHFFFAOYSA-N 0.000 claims 1
VLLIBRDRRLZBDW-UHFFFAOYSA-N 4,6-dichloro-5-nitro-2-pentylsulfanylpyrimidine Chemical compound CCCCCSC1=NC(Cl)=C([N+]([O-])=O)C(Cl)=N1 VLLIBRDRRLZBDW-UHFFFAOYSA-N 0.000 claims 1
LXJSJIXZOAMHTG-UHFFFAOYSA-N 4-(1,3-dimethyl-2,6-dioxo-7h-purin-8-yl)benzenesulfonic acid Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=C(S(O)(=O)=O)C=C1 LXJSJIXZOAMHTG-UHFFFAOYSA-N 0.000 claims 1
JNUSLIXQTFKAST-UHFFFAOYSA-N 4-hydroxy-5-nitro-2-(3,3,3-trifluoropropylsulfanyl)-1h-pyrimidin-6-one Chemical compound OC=1NC(SCCC(F)(F)F)=NC(=O)C=1[N+]([O-])=O JNUSLIXQTFKAST-UHFFFAOYSA-N 0.000 claims 1
DZCCDILNSAOYJL-UHFFFAOYSA-N 4-hydroxy-5-nitro-2-pentylsulfanyl-1h-pyrimidin-6-one Chemical compound CCCCCSC1=NC(=O)C([N+]([O-])=O)=C(O)N1 DZCCDILNSAOYJL-UHFFFAOYSA-N 0.000 claims 1
PHMVMACIFWKESN-UHFFFAOYSA-N 4-hydroxy-5-nitro-2-propylsulfanyl-1h-pyrimidin-6-one Chemical compound CCCSC1=NC(O)=C([N+]([O-])=O)C(O)=N1 PHMVMACIFWKESN-UHFFFAOYSA-N 0.000 claims 1
ZRTKYSSJSGXHGD-UHFFFAOYSA-N 5,7-bis(methylsulfanyl)-2h-triazolo[4,5-d]pyrimidine Chemical compound CSC1=NC(SC)=C2NN=NC2=N1 ZRTKYSSJSGXHGD-UHFFFAOYSA-N 0.000 claims 1
KYIGPHMUCNWSQZ-UHFFFAOYSA-N 5,7-bis(propylsulfanyl)-2h-triazolo[4,5-d]pyrimidine Chemical compound CCCSC1=NC(SCCC)=C2NN=NC2=N1 KYIGPHMUCNWSQZ-UHFFFAOYSA-N 0.000 claims 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
239000004475 Arginine Substances 0.000 claims 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
OHYMZEDKSOCZDL-UHFFFAOYSA-N C(C)N(C1=CC=CC=C1)CC.ClC1=NC(=NC(=C1[N+](=O)[O-])Cl)SCCC Chemical compound C(C)N(C1=CC=CC=C1)CC.ClC1=NC(=NC(=C1[N+](=O)[O-])Cl)SCCC OHYMZEDKSOCZDL-UHFFFAOYSA-N 0.000 claims 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
206010053567 Coagulopathies Diseases 0.000 claims 1
206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
206010051055 Deep vein thrombosis Diseases 0.000 claims 1
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 claims 1
208000005189 Embolism Diseases 0.000 claims 1
108010049003 Fibrinogen Proteins 0.000 claims 1
102000008946 Fibrinogen Human genes 0.000 claims 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
108010010803 Gelatin Proteins 0.000 claims 1
206010018364 Glomerulonephritis Diseases 0.000 claims 1
101710129448 Glucose-6-phosphate isomerase 2 Proteins 0.000 claims 1
108090000288 Glycoproteins Proteins 0.000 claims 1
102000003886 Glycoproteins Human genes 0.000 claims 1
239000007818 Grignard reagent Substances 0.000 claims 1
208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
241000700721 Hepatitis B virus Species 0.000 claims 1
102000007625 Hirudins Human genes 0.000 claims 1
108010007267 Hirudins Proteins 0.000 claims 1
238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 claims 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
239000005909 Kieselgur Substances 0.000 claims 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
239000004472 Lysine Substances 0.000 claims 1
229930195725 Mannitol Natural products 0.000 claims 1
229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 claims 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
QCOGKXLOEWLIDC-UHFFFAOYSA-N N-methylbutylamine Chemical compound CCCCNC QCOGKXLOEWLIDC-UHFFFAOYSA-N 0.000 claims 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
208000018262 Peripheral vascular disease Diseases 0.000 claims 1
102000000033 Purinergic Receptors Human genes 0.000 claims 1
108010080192 Purinergic Receptors Proteins 0.000 claims 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
206010040047 Sepsis Diseases 0.000 claims 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
229920002472 Starch Polymers 0.000 claims 1
235000021355 Stearic acid Nutrition 0.000 claims 1
229940122388 Thrombin inhibitor Drugs 0.000 claims 1
208000005485 Thrombocytosis Diseases 0.000 claims 1
206010043647 Thrombotic Stroke Diseases 0.000 claims 1
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
206010052779 Transplant rejections Diseases 0.000 claims 1
208000027418 Wounds and injury Diseases 0.000 claims 1
GCZABPLTDYVJMP-CBUXHAPBSA-N [(2r,3r,4r,5s)-5-acetyloxy-3,4-dibenzoyloxyoxolan-2-yl]methyl benzoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1OC(=O)C=1C=CC=CC=1)OC(=O)C=1C=CC=CC=1)OC(=O)C)OC(=O)C1=CC=CC=C1 GCZABPLTDYVJMP-CBUXHAPBSA-N 0.000 claims 1
QHIATDVFSBQTJE-UHFFFAOYSA-L [OH-].[Li+].O.[OH-].[Na+] Chemical compound [OH-].[Li+].O.[OH-].[Na+] QHIATDVFSBQTJE-UHFFFAOYSA-L 0.000 claims 1
230000003213 activating effect Effects 0.000 claims 1
206010000891 acute myocardial infarction Diseases 0.000 claims 1
239000002671 adjuvant Substances 0.000 claims 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
230000004931 aggregating effect Effects 0.000 claims 1
230000001270 agonistic effect Effects 0.000 claims 1
150000001340 alkali metals Chemical class 0.000 claims 1
229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
150000004703 alkoxides Chemical class 0.000 claims 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
229940024606 amino acid Drugs 0.000 claims 1
150000001413 amino acids Chemical class 0.000 claims 1
238000002399 angioplasty Methods 0.000 claims 1
230000002744 anti-aggregatory effect Effects 0.000 claims 1
239000003963 antioxidant agent Substances 0.000 claims 1
229940127218 antiplatelet drug Drugs 0.000 claims 1
239000011260 aqueous acid Substances 0.000 claims 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
206010003230 arteritis Diseases 0.000 claims 1
210000001367 artery Anatomy 0.000 claims 1
229960001230 asparagine Drugs 0.000 claims 1
229960005261 aspartic acid Drugs 0.000 claims 1
230000009286 beneficial effect Effects 0.000 claims 1
230000008901 benefit Effects 0.000 claims 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
238000012925 biological evaluation Methods 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
210000004369 blood Anatomy 0.000 claims 1
239000008280 blood Substances 0.000 claims 1
239000010836 blood and blood product Substances 0.000 claims 1
230000017531 blood circulation Effects 0.000 claims 1
208000015294 blood coagulation disease Diseases 0.000 claims 1
229940125691 blood product Drugs 0.000 claims 1
210000000481 breast Anatomy 0.000 claims 1
239000000872 buffer Substances 0.000 claims 1
239000006172 buffering agent Substances 0.000 claims 1
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
239000011575 calcium Substances 0.000 claims 1
229910052791 calcium Inorganic materials 0.000 claims 1
239000001506 calcium phosphate Substances 0.000 claims 1
229910000389 calcium phosphate Inorganic materials 0.000 claims 1
235000011010 calcium phosphates Nutrition 0.000 claims 1
239000002775 capsule Substances 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
229910002091 carbon monoxide Inorganic materials 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
210000004027 cell Anatomy 0.000 claims 1
239000001913 cellulose Substances 0.000 claims 1
235000010980 cellulose Nutrition 0.000 claims 1
229920002678 cellulose Polymers 0.000 claims 1
238000005119 centrifugation Methods 0.000 claims 1
230000008859 change Effects 0.000 claims 1
239000002738 chelating agent Substances 0.000 claims 1
125000001309 chloro group Chemical group Cl* 0.000 claims 1
230000009852 coagulant defect Effects 0.000 claims 1
239000003086 colorant Substances 0.000 claims 1
239000012230 colorless oil Substances 0.000 claims 1
230000000052 comparative effect Effects 0.000 claims 1
208000002528 coronary thrombosis Diseases 0.000 claims 1
210000004351 coronary vessel Anatomy 0.000 claims 1
238000005859 coupling reaction Methods 0.000 claims 1
238000004132 cross linking Methods 0.000 claims 1
239000012043 crude product Substances 0.000 claims 1
125000006165 cyclic alkyl group Chemical group 0.000 claims 1
230000006378 damage Effects 0.000 claims 1
RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims 1
238000000502 dialysis Methods 0.000 claims 1
JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
239000008298 dragée Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000010828 elution Methods 0.000 claims 1
229960005139 epinephrine Drugs 0.000 claims 1
229960001123 epoprostenol Drugs 0.000 claims 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
230000032050 esterification Effects 0.000 claims 1
238000005886 esterification reaction Methods 0.000 claims 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 claims 1
229940012952 fibrinogen Drugs 0.000 claims 1
239000002319 fibrinogen receptor antagonist Substances 0.000 claims 1
229910052731 fluorine Inorganic materials 0.000 claims 1
239000011737 fluorine Substances 0.000 claims 1
239000006260 foam Substances 0.000 claims 1
239000012458 free base Substances 0.000 claims 1
239000007789 gas Substances 0.000 claims 1
229920000159 gelatin Polymers 0.000 claims 1
239000008273 gelatin Substances 0.000 claims 1
235000019322 gelatine Nutrition 0.000 claims 1
235000011852 gelatine desserts Nutrition 0.000 claims 1
239000011521 glass Substances 0.000 claims 1
229960002442 glucosamine Drugs 0.000 claims 1
235000001727 glucose Nutrition 0.000 claims 1
150000002337 glycosamines Chemical class 0.000 claims 1
150000004795 grignard reagents Chemical class 0.000 claims 1
230000026030 halogenation Effects 0.000 claims 1
238000005658 halogenation reaction Methods 0.000 claims 1
230000002489 hematologic effect Effects 0.000 claims 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims 1
229940006607 hirudin Drugs 0.000 claims 1
229940106780 human fibrinogen Drugs 0.000 claims 1
CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Substances Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
229910000042 hydrogen bromide Inorganic materials 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
125000002883 imidazolyl group Chemical group 0.000 claims 1
238000000338 in vitro Methods 0.000 claims 1
238000001727 in vivo Methods 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
238000002347 injection Methods 0.000 claims 1
239000007924 injection Substances 0.000 claims 1
238000003780 insertion Methods 0.000 claims 1
230000037431 insertion Effects 0.000 claims 1
238000001990 intravenous administration Methods 0.000 claims 1
229910052740 iodine Inorganic materials 0.000 claims 1
239000011630 iodine Substances 0.000 claims 1
229910052742 iron Inorganic materials 0.000 claims 1
239000010410 layer Substances 0.000 claims 1
239000012280 lithium aluminium hydride Substances 0.000 claims 1
159000000003 magnesium salts Chemical class 0.000 claims 1
USSBDBZGEDUBHE-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O USSBDBZGEDUBHE-UHFFFAOYSA-L 0.000 claims 1
239000000594 mannitol Substances 0.000 claims 1
235000010355 mannitol Nutrition 0.000 claims 1
238000005259 measurement Methods 0.000 claims 1
230000007246 mechanism Effects 0.000 claims 1
239000012528 membrane Substances 0.000 claims 1
108020004084 membrane receptors Proteins 0.000 claims 1
102000006240 membrane receptors Human genes 0.000 claims 1
229910052987 metal hydride Inorganic materials 0.000 claims 1
150000004681 metal hydrides Chemical class 0.000 claims 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
239000008108 microcrystalline cellulose Substances 0.000 claims 1
235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
229940016286 microcrystalline cellulose Drugs 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
HNBDRPTVWVGKBR-UHFFFAOYSA-N n-pentanoic acid methyl ester Natural products CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 claims 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
125000004433 nitrogen atom Chemical group N* 0.000 claims 1
231100000252 nontoxic Toxicity 0.000 claims 1
230000003000 nontoxic effect Effects 0.000 claims 1
231100000956 nontoxicity Toxicity 0.000 claims 1
239000002777 nucleoside Substances 0.000 claims 1
125000003835 nucleoside group Chemical group 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
210000000056 organ Anatomy 0.000 claims 1
150000007530 organic bases Chemical class 0.000 claims 1
125000004430 oxygen atom Chemical group O* 0.000 claims 1
239000003002 pH adjusting agent Substances 0.000 claims 1
238000010647 peptide synthesis reaction Methods 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
238000002616 plasmapheresis Methods 0.000 claims 1
239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
229910052697 platinum Inorganic materials 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
159000000001 potassium salts Chemical class 0.000 claims 1
239000000843 powder Substances 0.000 claims 1
201000011461 pre-eclampsia Diseases 0.000 claims 1
239000003755 preservative agent Substances 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 claims 1
102000004169 proteins and genes Human genes 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 claims 1
239000008213 purified water Substances 0.000 claims 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
238000011002 quantification Methods 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
230000004044 response Effects 0.000 claims 1
238000012216 screening Methods 0.000 claims 1
239000003352 sequestering agent Substances 0.000 claims 1
229940076279 serotonin Drugs 0.000 claims 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims 1
229910000029 sodium carbonate Inorganic materials 0.000 claims 1
239000001509 sodium citrate Substances 0.000 claims 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
239000008247 solid mixture Substances 0.000 claims 1
238000001694 spray drying Methods 0.000 claims 1
239000003381 stabilizer Substances 0.000 claims 1
230000000087 stabilizing effect Effects 0.000 claims 1
239000008107 starch Substances 0.000 claims 1
235000019698 starch Nutrition 0.000 claims 1
239000008117 stearic acid Substances 0.000 claims 1
235000000346 sugar Nutrition 0.000 claims 1
125000004434 sulfur atom Chemical group 0.000 claims 1
239000000829 suppository Substances 0.000 claims 1
239000012730 sustained-release form Substances 0.000 claims 1
239000003765 sweetening agent Substances 0.000 claims 1
238000003786 synthesis reaction Methods 0.000 claims 1
239000003826 tablet Substances 0.000 claims 1
239000000454 talc Substances 0.000 claims 1
229910052623 talc Inorganic materials 0.000 claims 1
235000012222 talc Nutrition 0.000 claims 1
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims 1
AFCAKJKUYFLYFK-UHFFFAOYSA-N tetrabutyltin Chemical compound CCCC[Sn](CCCC)(CCCC)CCCC AFCAKJKUYFLYFK-UHFFFAOYSA-N 0.000 claims 1
239000003868 thrombin inhibitor Substances 0.000 claims 1
239000003634 thrombocyte concentrate Substances 0.000 claims 1
206010043554 thrombocytopenia Diseases 0.000 claims 1
230000017423 tissue regeneration Effects 0.000 claims 1
238000005809 transesterification reaction Methods 0.000 claims 1
230000008733 trauma Effects 0.000 claims 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 claims 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
229940038773 trisodium citrate Drugs 0.000 claims 1
241001529453 unidentified herpesvirus Species 0.000 claims 1
230000002792 vascular Effects 0.000 claims 1
210000003462 vein Anatomy 0.000 claims 1
239000001993 wax Substances 0.000 claims 1
239000000080 wetting agent Substances 0.000 claims 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL96324396A 1995-07-11 1996-07-04 Nowe inhibitory skupiania się płytek krwi PL182680B1 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9514074.5A GB9514074D0 (en)	1995-07-11	1995-07-11	Compounds
GBGB9520311.3A GB9520311D0 (en)	1995-10-05	1995-10-05	Compounds
GBGB9522837.5A GB9522837D0 (en)	1995-11-08	1995-11-08	Compounds
PCT/SE1996/000911 WO1997003084A1 (en)	1995-07-11	1996-07-04	New inhibitors of platelet aggregation

Publications (2)

Publication Number	Publication Date
PL324396A1 PL324396A1 (en)	1998-05-25
PL182680B1 true PL182680B1 (pl)	2002-02-28

Family

ID=27267806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL96324396A PL182680B1 (pl)	1995-07-11	1996-07-04	Nowe inhibitory skupiania się płytek krwi

Country Status (25)

Country	Link
US (1)	US5747496A (2)
EP (1)	EP0840740B1 (2)
JP (1)	JP4084415B2 (2)
KR (1)	KR100444123B1 (2)
CN (1)	CN1069321C (2)
AR (1)	AR003453A1 (2)
AT (1)	ATE217010T1 (2)
AU (1)	AU699034B2 (2)
BR (1)	BR9609467A (2)
CA (1)	CA2226758A1 (2)
CZ (1)	CZ297200B6 (2)
DE (1)	DE69621021T2 (2)
EE (1)	EE03616B1 (2)
HU (1)	HU221880B1 (2)
IL (1)	IL122814A (2)
IS (1)	IS1790B (2)
MY (1)	MY116542A (2)
NO (1)	NO310624B1 (2)
NZ (1)	NZ312258A (2)
PL (1)	PL182680B1 (2)
SA (1)	SA96170272B1 (2)
SK (1)	SK283206B6 (2)
TR (1)	TR199800019T1 (2)
TW (1)	TW427996B (2)
WO (1)	WO1997003084A1 (2)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6297232B1 (en) *	1996-12-20	2001-10-02	Astrazeneca Ab	Triazolo[4,5-D]pyrimidinyl derivatives and their use as medicaments
SE9702773D0 (sv) *	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
SE9702774D0 (sv) *	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
AR017014A1 (es) *	1997-07-22	2001-08-22	Astrazeneca Ab	Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
SE9702772D0 (sv) *	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
MXPA00007634A (es) *	1998-02-17	2003-09-10	Astrazeneca Uk Ltd	Nuevos compuestos de triazol (4,5-d) pirimidina.
SE9802574D0 (sv) *	1998-07-17	1998-07-17	Astra Pharma Prod	Novel compounds
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904128D0 (sv) *	1999-11-15	1999-11-15	Astra Pharma Prod	Novel compounds
SE9904129D0 (sv) *	1999-11-15	1999-11-15	Astra Pharma Prod	Novel compounds
SE9904377D0 (sv) *	1999-12-01	1999-12-01	Astra Pharma Prod	Pharmaceutical combinations
GB0013407D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound
GB0013488D0 (en)	2000-06-02	2000-07-26	Astrazeneca Ab	Chemical compound
AR039558A1 (es) *	2000-08-21	2005-02-23	Inspire Pharmaceuticals Inc	Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7132408B2 (en)	2000-08-21	2006-11-07	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
US6897201B2 (en) *	2000-08-21	2005-05-24	Inspire Pharmaceuticals, Inc.	Compositions and methods for the treatment of glaucoma or ocular hypertension
US7115585B2 (en)	2000-08-21	2006-10-03	Inspire Pharmaceuticals, Inc.	Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en)	2000-08-21	2008-11-18	Inspire Pharmaceuticals, Inc.	Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en)	2000-08-21	2006-03-28	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
GB0100624D0 (en) *	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VII
SE0101932D0 (sv) *	2001-05-31	2001-05-31	Astrazeneca Ab	Pharmaceutical combinations
US20020169730A1 (en) *	2001-08-29	2002-11-14	Emmanuel Lazaridis	Methods for classifying objects and identifying latent classes
US7435724B2 (en)	2002-02-27	2008-10-14	Inspire Pharmaceutical, Inc.	Degradation-resistant mononucleoside phosphate compounds
EP1618109A2 (en) *	2003-04-09	2006-01-25	Biogen Idec MA Inc.	Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
WO2004092170A2 (en) *	2003-04-09	2004-10-28	Biogen Idec Ma Inc.	Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
EP1633756B1 (en) *	2003-04-09	2008-12-24	Biogen Idec MA Inc.	A2a adenosine receptor antagonists
EP1615931A1 (en) *	2003-04-09	2006-01-18	Biogen Idec MA Inc.	Triazolopyrazines and methods of making and using the same
WO2004092171A2 (en) *	2003-04-09	2004-10-28	Biogen Idec Ma Inc.	Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
JP2007509180A (ja) *	2003-10-21	2007-04-12	インスパイアーファーマシューティカルズ，インコーポレイティド	疼痛を治療するための、非ヌクレオチド組成物および方法
DE602004027409D1 (de) *	2003-10-21	2010-07-08	Inspire Pharmaceuticals Inc	Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7335648B2 (en) *	2003-10-21	2008-02-26	Inspire Pharmaceuticals, Inc.	Non-nucleotide composition and method for inhibiting platelet aggregation
US7504497B2 (en) *	2003-10-21	2009-03-17	Inspire Pharmaceuticals, Inc.	Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7749981B2 (en) *	2003-10-21	2010-07-06	Inspire Pharmaceuticals, Inc.	Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7932376B2 (en) *	2005-05-05	2011-04-26	Inspire Pharmaceuticals, Inc.	Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
JP2010508350A (ja) *	2006-10-31	2010-03-18	ヤンセンファーマシューティカエヌ．ベー．	Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
UA100864C2 (uk) *	2007-12-03	2013-02-11	Астразенека Аб	Спосіб лікування або запобігання аневризмі черевної аорти
GB0906579D0 (en)	2009-04-16	2009-05-20	Vernalis R&D Ltd	Pharmaceuticals, compositions and methods of making and using the same
US8470834B2 (en) *	2008-08-20	2013-06-25	Merck Sharp & Dohme Corp.	AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011101740A1 (en)	2010-02-16	2011-08-25	Actavis Group Ptc Ehf	Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
JP2015500219A (ja)	2011-11-30	2015-01-05	アクタビス・グループ・ピーティーシー・イーエイチエフ	新規な結晶形を有するチカグレロル及びその調製方法
WO2014083139A1 (en)	2012-11-29	2014-06-05	Actavis Group Ptc Ehf	Novel amorphous form of ticagrelor
WO2014206187A1 (zh)	2013-06-24	2014-12-31	苏州明锐医药科技有限公司	替卡格雷及其中间体的制备方法
WO2014206188A1 (zh) *	2013-06-27	2014-12-31	苏州明锐医药科技有限公司	替格瑞洛的制备方法
CN105061431B (zh) *	2015-07-28	2017-03-29	山东百诺医药股份有限公司	6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN112876485A (zh) *	2021-01-25	2021-06-01	郭丽伟	一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
CN112915063B (zh) *	2021-01-25	2022-12-20	刘红枚	一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
RU2770405C1 (ru) *	2021-07-05	2022-04-15	федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Производные триазола, проявляющие антиагрегационную активность

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4742064A (en) *	1985-09-10	1988-05-03	Regents Of The University Of Minnesota	Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) *	1988-11-09	1988-12-14	Wellcome Found	Heterocyclic compounds
JP2619710B2 (ja) *	1989-02-27	1997-06-11	日本製紙株式会社	２′，３′−ジデオキシプリンヌクレオシド類の製造方法
WO1994018215A1 (en) *	1993-02-03	1994-08-18	Gensia, Inc.	Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
IL108523A0 (en) *	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain

1996
- 1996-07-04 WO PCT/SE1996/000911 patent/WO1997003084A1/en not_active Ceased
- 1996-07-04 CA CA002226758A patent/CA2226758A1/en not_active Abandoned
- 1996-07-04 AT AT96923160T patent/ATE217010T1/de not_active IP Right Cessation
- 1996-07-04 TW TW085108062A patent/TW427996B/zh not_active IP Right Cessation
- 1996-07-04 TR TR1998/00019T patent/TR199800019T1/xx unknown
- 1996-07-04 DE DE69621021T patent/DE69621021T2/de not_active Expired - Fee Related
- 1996-07-04 JP JP50574897A patent/JP4084415B2/ja not_active Expired - Fee Related
- 1996-07-04 CZ CZ0002598A patent/CZ297200B6/cs not_active IP Right Cessation
- 1996-07-04 NZ NZ312258A patent/NZ312258A/xx unknown
- 1996-07-04 IL IL12281496A patent/IL122814A/en not_active IP Right Cessation
- 1996-07-04 EP EP96923160A patent/EP0840740B1/en not_active Expired - Lifetime
- 1996-07-04 KR KR10-1998-0700187A patent/KR100444123B1/ko not_active Expired - Fee Related
- 1996-07-04 SK SK23-98A patent/SK283206B6/sk unknown
- 1996-07-04 PL PL96324396A patent/PL182680B1/pl not_active IP Right Cessation
- 1996-07-04 HU HU9802448A patent/HU221880B1/hu active IP Right Grant
- 1996-07-04 US US08/737,005 patent/US5747496A/en not_active Expired - Fee Related
- 1996-07-04 CN CN96196720A patent/CN1069321C/zh not_active Expired - Fee Related
- 1996-07-04 BR BR9609467A patent/BR9609467A/pt active Search and Examination
- 1996-07-04 EE EE9800026A patent/EE03616B1/xx not_active IP Right Cessation
- 1996-07-04 AU AU63751/96A patent/AU699034B2/en not_active Ceased
- 1996-07-11 MY MYPI96002866A patent/MY116542A/en unknown
- 1996-07-11 AR ARP960103538A patent/AR003453A1/es active IP Right Grant
- 1996-08-28 SA SA96170272A patent/SA96170272B1/ar unknown
1998
- 1998-01-08 NO NO19980080A patent/NO310624B1/no unknown
- 1998-01-08 IS IS4647A patent/IS1790B/is unknown

Also Published As

Publication number	Publication date
HUP9802448A2 (hu)	1999-05-28
JPH11508914A (ja)	1999-08-03
AU6375196A (en)	1997-02-10
CN1069321C (zh)	2001-08-08
AR003453A1 (es)	1998-08-05
IL122814A (en)	2001-04-30
NZ312258A (en)	1999-08-30
SK2398A3 (en)	1999-01-11
HUP9802448A3 (en)	2000-03-28
SK283206B6 (sk)	2003-03-04
CZ297200B6 (cs)	2006-09-13
EE9800026A (et)	1998-08-17
JP4084415B2 (ja)	2008-04-30
MY116542A (en)	2004-02-28
EP0840740A1 (en)	1998-05-13
KR100444123B1 (ko)	2004-10-14
CN1195353A (zh)	1998-10-07
AU699034B2 (en)	1998-11-19
CA2226758A1 (en)	1997-01-30
DE69621021T2 (de)	2002-10-31
CZ2598A3 (cs)	1998-08-12
ATE217010T1 (de)	2002-05-15
SA96170272B1 (ar)	2006-06-04
HU221880B1 (hu)	2003-02-28
IS4647A (is)	1998-01-08
NO310624B1 (no)	2001-07-30
EP0840740B1 (en)	2002-05-02
NO980080L (no)	1998-03-06
KR19990028885A (ko)	1999-04-15
BR9609467A (pt)	1999-03-02
EE03616B1 (et)	2002-02-15
IS1790B (is)	2001-11-28
TW427996B (en)	2001-04-01
NO980080D0 (no)	1998-01-08
MX9800308A (es)	1998-09-30
US5747496A (en)	1998-05-05
WO1997003084A1 (en)	1997-01-30
IL122814A0 (en)	1998-08-16
TR199800019T1 (xx)	1998-05-21
PL324396A1 (en)	1998-05-25
DE69621021D1 (de)	2002-06-06

Legal Events

Date	Code	Title	Description
2009-09-30	LAPS	Decisions on the lapse of the protection rights	Effective date: 20080704

Publication	Publication Date	Title
EP0840740B1 (en)	2002-05-02	New inhibitors of platelet aggregation
FI110687B (fi)	2003-03-14	Menetelmä valmistaa N-alkyyli-2-substituoituja ATP-analogeja
FI101793B (fi)	1998-08-31	Menetelmä uusien, terapeuttisesti käyttökelpoisten 9-purinyylifosfonih appojohdannaisten valmistamiseksi
JP3141028B2 (ja)	2001-03-05	Ａｔｐ類似体
HK1002936B (en)	1998-09-25	N-alkyl-2-substituted atp analogues
US5654285A (en)	1997-08-05	ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
RU2174518C2 (ru)	2001-10-10	Производные 3-н-1,2,3-триазоло-[4,5-d]пиримидина, фармацевтическая композиция и способ их получения
MXPA98000308A (en)	1998-11-16	New plaque aggregation inhibitors
UA64697C2 (en)	2004-03-15	Platelet aggregation inhibitors
AU648885C (en)	1995-06-01	ATP analogues